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ABSTRACT
The aim of this study was to study the effectiveness of the Swenerton score in assessing extent of disease as an
independent prognostic and predictive factor in patients with metastatic breast cancer (MBC) who receive
high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplant (AHSCT). Two-hun-
dred thirty-two patients with MBC underwent HDCT. Extent of disease was assessed quantitatively using the
Swenerton score. A retrospective analysis was performed using Cox proportional hazards regression and
logistic regression models. One hundred three (44%) patients had a complete response (CR) after HDCT.
Bone marrow as source of hematopoietic stem cells, hormone-receptor–negative status, and visceral involve-
ment correlated with both worse overall survival (OS) and progression-free survival (PFS). Short disease-free
interval, multiple sites of metastatic disease, and less than 50% reduction in the Swenerton Score during
induction chemotherapy correlated with worse OS. Patients in CR at the time of HDCT had better PFS than
patients in partial response, stable disease, or progressive disease. Fifty-six patients who underwent conversion
to CR after HDCT had a similar median OS (not reached v 74 months; P  .51) and PFS duration (22 v 44
months; P  .15) as patients who received HDCT after a CR to standard-dose chemotherapy (SDCT).
Conversion to CR was predicted by a >50% reduction in the Swenerton score during SDCT (odds ratio [OR]
3.32, P < .01) and soft-tissue disease (OR 4.08, P < .01). The presence of multiple metastatic sites predicted
decreased probability of conversion to CR (OR 0.34, P < .01). The Swenerton score provides a thorough
estimate of disease extent, and reduction of Swenerton score by SDCT is potentially useful for selecting the
optimal candidates for HDCT trials who may achieve long-term disease control.
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INTRODUCTION
High-dose chemotherapy (HDCT) combined
with autologous hematopoietic stem cell transplanta-
tion (AHSCT) has been extensively studied as a pos-
sible strategy to improve antitumor responses in pa-
tients with metastatic breast cancer [1-7]. Despite a
quite large number of phase II trials, only 4 random-
ized clinical trials comparing HDCT with conven-
tional chemotherapy are available to date, all of which
fail to show any improvement in overall survival rate
in favor of HDCT.
The only fully published randomized clinical trial
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compared a HDCT regimen of carboplatin, cyclo-
phosphamide, and thiotepa (STAMP V) with contin-
ued cyclophosphamide, methotrexate, and 5-ﬂuoro-
uracil (CMF) in patients responding to conventional
cyclophosphamide, doxorubicin, and 5-ﬂuorouracil or
CMF (PBT1 trial) [8]. The intent-to-treat analysis of
184 patients showed no difference in overall survival
rate (OS) or progression-free survival rate (PFS) be-
tween the 2 groups. A recently reported subgroup
analysis of this trial has shown a possible survival
advantage related to HDCT in younger women [9]. A
small French randomized clinical trial showed a sub-
stantial survival advantage with HDCT, although it
was not statistically signiﬁcant [10]. Recently, 2 other
phase III trials have shown a PFS advantage in favor of
HDCT and no OS difference [11,12]. Whether these
results have to be considered a ﬁnal negative answer to
the issue of the worth of HDCT in metastatic breast
cancer is debatable. In fact, the PBT1 trial, considered
by most the strongest evidence against HDCT in
metastatic breast cancer, simply shows that, in patients
responding to conventional chemotherapy, one single
administration of HDCT is equal to up to 24 months
of continuous CMF, a conventional approach that is
not widespread. One might view this result as sup-
porting the HDCT concept. Moreover, the baseline
prognosis of patients enrolled in HDCT trials is bet-
ter than the general population of breast cancer pa-
tients because of selection criteria [13]. It is, therefore,
arguable that the survival beneﬁt hypothesized in fa-
vor of HDCT has been overestimated, with obvious
consequences for the sample size of the trials, which is
inadequate to detect any smaller, but clinically mean-
ingful, difference. Hence, the role of HDCT in the
treatment of metastatic breast cancer (MBC) is still an
open question, and trials designed to target speciﬁc
subpopulations of MBC are needed [14,15].
In an effort to identify prognostic and predictive
factors for patients undergoing HDCT, we analyzed
factors related to OS and PFS in patients with meta-
static breast cancer who were receiving HDCT at our
institution. The survival rate of patients who under-
went conversion to complete response (CR) by
HDCT was compared with that of patients receiving
HDCT as consolidation treatment for a CR achieved
with induction standard-dose chemotherapy (SDCT).
Because the outcome of these 2 groups of patients was
similar, we then focused our attention on factors pre-
dictive of conversion to CR among patients with mea-
surable disease after induction SDCT.
Metastatic tumor burden has been identiﬁed as an
independent predictor of outcome in patients receiv-
ing both SDCT [16,17] and HDCT [3,5,18]. How-
ever, tumor burden has never been explored quanti-
tatively in patients with HDCT. Thus, we explored
whether a better deﬁnition of the extent of disease and
changes in the extent of disease as a consequence of
induction SDCT could identify patients who could
beneﬁt best from HDCT. In previous reports, the
measuring system developed by Swenerton et al [19]
was shown to accurately predict tumor response and
survival rates in patients with metastatic breast cancer
who underwent SDCT [16,17,19]. We used the Swen-
erton system in the current study to compare tumor
burden quantitatively before induction SDCT and
before HDCT.
PATIENTS AND METHODS
The study involved 232 women with the histologic
diagnosis of metastatic breast cancer who underwent
HDCT/AHSCT in phase II studies at The University
of Texas M. D. Anderson Cancer Center between
August 1991 and December 1998. The HDCT regi-
men consisted of cyclophosphamide, carmustine, and
thiotepa (CBT), and the AHSCT involved either bone
marrow or peripheral blood stem cells. Before initia-
tion of HDCT, patients received induction SDCT
with the intent of maximizing tumor response. The
protocols were reviewed and approved by the M. D.
Anderson Institutional Review Board, and written in-
formed consent was obtained from all patients.
To be eligible for HDCT, patients had to be
between 18 and 65 years of age and have a Zubrod
performance status of 1; an estimated creatinine
clearance greater than 60 mL/min; serum glutamate
oxaloacetate transaminase, serum glutamate pyruvate
transaminase, and bilirubin levels less than 2 times the
upper limits of normal; adequate cardiac function (left
ventricular ejection fraction 50%); and adequate
pulmonary function (carbon dioxide diffusion capacity
50% of predicted levels). Patients with metastatic
disease who achieved CR with surgery or radiation
therapy were eligible to participate without receiving
induction SDCT.
Extent of Disease: Swenerton Scoring System
The extent of metastatic disease was assessed
quantitatively using the scoring system developed by
Swenerton et al [19]. Brieﬂy, the following anatomic
sites were examined: ipsilateral breast, contralateral
breast, lymph nodes, skin/chest wall, lung, pleura,
liver, mediastinum, abdominal and pelvic cavity, bone,
bone marrow, and central nervous system. A value was
assigned to describe the extent of disease at each site as
follows: 0, no disease; 1, strong suspicion of involve-
ment but insufﬁcient laboratory or clinical informa-
tion to deﬁne further; 2, minimal involvement; 5,
moderate involvement; and 10 extensive involvement.
The criteria for determining extent of disease at the
various anatomic sites are summarized in Table 1. The
total burden of metastatic disease was estimated as the
sum of the scores for tumor extent at all known disease
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sites. The maximum extent of metastatic disease be-
fore induction chemotherapy and the extent of meta-
static disease just before HDCT was begun were ob-
tained and classiﬁed according to the cut-off values
documented in the original reports (6, 6 to 12, 13 to
20, and 20). The percent reduction in the scores
during induction SDCT was also determined.
Definitions
Standard criteria were used to deﬁne CR, partial
response (PR), stable disease (SD), and progressive
disease (PD) [20]. Patients were grouped according to
3 categories of response: CR/CR, patients who at-
tained a CR to induction chemotherapy and main-
tained that CR after transplant; NoCR/CR, patients
who attained less than a CR to induction chemother-
apy but attained a CR as a result of HDCT; and
NoCR, patients who did not attained a CR.
PFS was deﬁned as the interval between the date
of the transplant and the documented date of disease
progression or death from any cause. OS was deﬁned
as the interval between the date of transplant and
death. Early death (ED) was deﬁned as death within
100 days after the transplant. All cases of early death in
this analysis were attributable to the toxicity of the
HDCT or to complications from infections. Patients
who were still alive at the time of the analysis were
censored at the last follow-up date (updated as of June
2002).
Treatment
The high-dose CBT regimen was administered on
days 6 through 4 as follows: cyclophosphamide, 2
g/m2 intravenously (IV) over 2 hours (total dose 6
g/m2); thiotepa, IV 240 mg/m2 over 4 hours (total
dose 720 mg/m2); and carmustine, IV 150 mg/m2 over
2 hours (total dose 450 mg/m2). Mesna was adminis-
tered at 500 mg/m2 before the ﬁrst dose of cyclophos-
phamide and then at 2 g/m2 as a continuous IV infu-
sion daily until 24 hours after completion of
cyclophosphamide. AHSCT infusion was done on
day 0.
One hundred forty-six patients received mobiliza-
tion chemotherapy for peripheral blood stem cell col-
lection. This treatment was delivered on days 1
through 3 and consisted of cyclophosphamide, 1.5
g/m2 IV; etoposide, 250 mg/m2 IV; and cisplatin, 40
mg/m2 IV with granulocyte colony-stimulating factor
alone or in combination with interleukin-3 or throm-
bopoietin. The autologous peripheral blood stem cells
or bone marrow were cryopreserved in dimethyl sul-
foxide by programmed freezing according to standard
techniques. Purging or positive selection of stem cells
was not performed.
Statistical Analysis
Cox proportional hazards regression models were
used to assess the association of each potential prog-
nostic factor with PFS and with survival in a univariate
fashion. All factors, regardless of whether they were
found to be statistically signiﬁcant in the univariate
analysis, were then analyzed together in a multivariate
Cox proportional hazards regression model. Factors
were included in a saturated model and then removed
one at a time through a backward elimination variable
selection method using the likelihood ratio test until
all remaining factors were statistically signiﬁcant (P 
Table 1. Swenerton Criteria to Determine Extent of Disease at
Different Anatomic Sites
Sites and Categories Criteria
Breast, chest wall,
lymph nodes
Minimal <2 lesions, largest lesion < 2.5 cm
Moderate 3-5 lesions, largest lesion 2.5-5 cm or
confluent lesions <10 cm
diameter
Extensive >5 lesions, or largest lesion >5 cm,
or confluent lesions >10-cm
diameter
Lung
Minimal <2 lesions, largest <2 cm
Moderate 3-5 lesions, largest <2 cm
Extensive >5 lesions or largest >2 cm or
lymphangitic spread
Pleura
Minimal Blunting of costovertebral angle,
cytological confirmation required
Moderate <50% filling of pleural cavity
Extensive >50% filling of pleural cavity or
bilateral effusions
Liver
Minimal Single lesion, no hepatomegaly
Moderate Multiple lesions, no hepatomegaly
Extensive Hepatomegaly and/or jaundice
(bilirubin 2 > mg/100 mL)
Mediastinum, intra-
abdominal, intra-
pelvic
Minimal Operative findings only, not
demonstrable radiologically
Moderate Demonstrable by radiological means,
but no obstruction-compression
symptoms
Extensive Palpable mass, or obstruction-
compression symptoms
Bone marrow
Minimal Focal clumps of tumor on biopsy, no
peripheral cytopenias
Moderate Diffuse involvement of bone marrow,
but no peripheral cytopenias
Extensive Diffuse replacement and cytopenias
Bone
Minimal 1-2 lesions demonstrable
radiologically or on bone scan
Moderate 3-5 lesions
Extensive >5 lesions
Central nervous
system and ascites
Always indicates extensive disease
F. Montemurro et al.
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.05). The analysis of PFS was performed in the same
manner as the analysis of survival, with the event
deﬁned as death from any cause or progression.
Factors related to the probability of a CR to
HDCT (conversion) were studied in the subset of 175
patients who received induction chemotherapy and
underwent HDCT still with measurable disease
(PRSDPD) by logistic regression analysis. The
odds ratio (OR) was estimated for the strata of each of
the potential prognostic factors.
RESULTS
Patient Characteristics and Response to
High-Dose Chemotherapy
A total of 232 patients with metastatic breast can-
cer underwent HDCT with the CBT regimen (Table
2). All patients were women. Median age at HDCT
was 45 years (range, 30 to 65 years). The median
number of metastatic sites per patient was 2 (range, 1
to 7). One hundred seventy-two had experienced a
metastatic relapse after initial treatment for primary
breast cancer, and 60 had metastatic disease at the
time of diagnosis.
Two hundred-twenty patients received induction
chemotherapy for treatment of metastatic disease; 116
received an anthracycline, 48 taxanes, and 33 both a
taxane and an anthracycline. The remaining patients
received various combinations of cyclophosphamide,
methotrexate, 5-ﬂuorouracil, vinblastine, and etopo-
side. Twelve patients underwent HDCT without in-
duction chemotherapy for metastatic disease: 5 of
them had their metastases surgically removed (surgical
CR), 3 had SD or PR after receiving radiation therapy
on metastatic sites, and 4 experienced tumor progres-
sion during or just after adjuvant treatment for pri-
mary breast cancer and received HDCT as salvage
treatment.
At the time of HDCT, 50 patients were in CR
(22%), 128 in PR (55%), 35 in SD (15%), and 19 (8%)
had evidence of disease progression. Eleven patients
achieved CR by surgical resection of residual disease
after induction chemotherapy. Another patient with
metastatic bone disease achieved CR conﬁrmed by
biopsy after induction chemotherapy followed by ra-
diation therapy. The median number of cycles of in-
duction chemotherapy administered was 5 (range, 1 to
18). Among patients who attained a CR to induction
chemotherapy, the median number of cycles adminis-
tered was 5 (range, 1 to 11).
The median extent of disease at any time as as-
sessed by the Swenerton score was 10 (range, 2 to 54).
The median Swenerton score at initiation of HDCT
was 5 (range, 0 to 30). Median interval from study
registration (and the beginning of blood stem cell or
bone marrow collection) to HDCT was 40 days. The
Table 2. Characteristics of 232 Patients
No. (%)*
Median age at HDCT, yr (range) 45 (30-65)
Stage at diagnosis
I 29 (12)
IIA/B 108 (47)
IIIA/B 33 (14)
IV 60 (26)
Unknown 2 (1)
Hormone receptor status
ER and/or PgR positive 129 (56)
ER and PgR negative 80 (34)
Receptors unknown 23 (10)
Neoadjuvant/adjuvant chemotherapy
Not applicable 60 (26)
Yes 144 (62)
No 28 (12)
Adjuvant anthracyline
Not applicable 60 (26)
Yes 96 (41)
No 76 (33)
Adjuvant endocrine therapy
Not applicable 60 (26)
Yes 50 (22)
No 122 (53)
Adjuvant radiation therapy
Not applicable 60 (26)
Yes 58 (25)
No 114 (49)
Time from diagnosis to metastasis
Upfront stage IV 60 (26)
1-23 months 85 (37)
>23 months 87 (37)
Dominant site of metastases
Soft tissue 67 (29)
Bone 71 (31)
Visceral, non liver 50 (22)
Liver 44 (19)
Number of metastatic sites
1 110 (47)
2 76 (33)
3 27 (12)
>3 19 (8)
Maximum extent of the disease†
<6 73 (31)
6-12 79 (34)
13-20 43 (18)
>20 37 (16)
Number of relapses before transplant
1 157 (68)
2 53 (23)
>2 22 (9)
Number of conventional SDCT regimens
for metastatic disease
0 12 (5)
1 180 (78)
>1 40 (17)
Prior endocrine therapy for metastatic disease
Yes 43 (19)
No 189 (81)
Extent of the disease before HDCT†
<6 149 (64)
6-12 59 (25)
13-20 17 (7)
>20 7 (3)
Status before HDCT
CR 50 (22)
PR 128 (55)
SD 35 (15)
PD 19 (8)
HDCT indicates high-dose chemotherapy; ER, estrogen recep-
tor; PgR, progesterone receptor; SDCT, standard-dose chemother-
apy; SD, stable disease; PD, progressive disease.
*Because of rounding, the percentages do not always equal 100.
†Measured according to the Swenerton scoring system.
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source of hematopoietic cells was bone marrow in 79
patients (34%), peripheral blood progenitor cells in
148 patients (64%), and both in 5 patients (2%).
After HDCT/AHSCT, the tumor response was
CR in 103 patients (44%; 95% conﬁdence interval
[CI], 38% to 51%), PR in 40 patients (17%; 95% CI,
13% to 23%), stable disease in 64 (28%; 95% CI, 22%
to 34%), and progressive disease in 14 patients (6%;
95% CI, 3% to 10%; Table 3). Fifty-six of 182 pa-
tients who had measurable disease at the time of
HDCT achieved CR (conversion rate No CR to CR,
31%: 95% CI, 23% to 37%). The pre-HDCT status
of these 56 converting patients was PR in 46, SD in 7,
and PD in 3. Eleven patients died of acute transplant-
related adverse events, and 2 died of delayed lung
toxicity and infection (for a combined mortality rate of
5.6%). Eight of the 11 patients who died of acute
transplant-related complications had received bone
marrow as source of hematopoietic stem cells. No
toxicity-related deaths occurred among patients who
underwent HDCT during the last 2 years of this
study.
At the time of this analysis, median follow-up for
living patients was 56 months (range, 17 to 123
months). Eighty patients were alive, and 42 of them
were free of disease progression. Median survival and
median PFS were 36 and 12 months, respectively. The
estimated 5-year survival and PFS were 34% (95% CI,
28% to 41%) and 19% (95% CI, 15% to 26%).
When patients who achieved a CR after HDCT
were compared with patients who did not, there was a
signiﬁcant difference in survival rate(median, 74
months v 21 months, P  .01) and PFS (median, 22
months v 7 months respectively; P  .01). Median
survival rate was not reached for patients receiving
HDCT while in CR (CR/CR). Survival rate for this
group was not signiﬁcantly different from the patients
who converted from measurable disease to CR (No
CR/CR; P  .44). There was a trend for a shorter
median PFS for patients who underwent conversion
from measurable disease to CR (22 months) versus
those patients who received HDCT while in CR (44
months), but this trend was not statistically signiﬁcant
(P  .15; Figure 1).
Prognostic Factors for PFS and Survival
The results of the univariate analysis of factor
associated with survival and PFS are summarized in
Table 4. Cox proportional hazards multiple regression
analysis showed that the following prognostic factors
were associated with a shorter survival (Table 5): bone
marrow, either alone or mixed with peripheral blood
progenitor cells, as source of hematopoietic cells (haz-
ard ratio [HR] 2.00; P  .01); negative hormone
receptor status (HR 2.13; P  .01); a disease-free
interval before transplant of less than 24 months (HR
1.61; P  .01); number of metastatic sites (2 HR 1.96;
P  .01; 3 HR 2.79; P  .01); visceral disease (HR
1.77, P .01); and a 50% or less change in Swenerton
score (HR 2.08, P  .01).
For PFS, poor prognostic factors included bone
marrow, either alone or mixed with peripheral blood
progenitor cells, as source of hematopoietic cells (HR
1.39; P  .04), negative hormone receptor status (HR
1.89; P  .01), visceral involvement (HR 1.84; P 
.01), and PR before HDCT (HR 2.36; P  .01), SD
before HDCT (HR 2.67; P  .01), or PD before
HDCT (HR 4.21; P  .01).
Predictive Variables—Conversion to CR by HDCT
One hundred eighty-two patients underwent
HDCT with measurable disease. For the analysis of
conversion into CR, we selected patients who received
induction chemotherapy and no additional surgery or
radiation therapy for metastatic disease that could
have inﬂuenced their response status either before or
after HDCT. This led to the exclusion of 7 patients: 3
patients underwent HDCT without conventional in-
duction chemotherapy, one achieved a PR to radiation
therapy before HDCT, and another 3 achieved a CR
by metastasectomy after HDCT. Thus, 175 patients
were eligible for the analysis of conversion. The pre-
HDCT status of these patients was PR in 127, SD in
33, and PD in 15. Fifty-three of these patients con-
verted to CR after HDCT (conversion rate 30%; 95%
CI, 24% to 38%). The likelihood of a CR to HDCT
was analyzed by univariate and multivariate logistic
regression using the same set of variables used to
analyze OS and PFS.
The percent reduction in extent of disease (Swen-
erton score) achieved by induction chemotherapy was
also determined. The median reduction in Swenerton
score was 50% (range, 0 to 90%). Table 6 shows the
conversion into CR according to the reduction in
Swenerton score in the whole subset of patients and in
the 127 patients achieving a PR according to the
World Health Organization criteria. The 127 patients
who achieved a PR by conventional criteria had vari-
Table 3. Status of the Patients before and after High-Dose CBT
Before
HDCT
After HDCT
N (%) CR PR SD PD ED
CR 50 (22%) 47 — — — 3
PR 128 (55%) 46 30 38 8 6
SD 35 (15%) 7 4 20 3 1
PD 19 (8%) 3 6 6 3 1
103
(44%)
40
(17%)
64
(28%)
14
(6%)
11
(5%)
CBT indicates cyclophosphamide, carmustine, and thiotepa;
HDCT, high-dose chemotherapy; SD, stable disease; PD, progres-
sive disease; ED, early death.
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able reductions in extent of disease on the basis of the
Swenerton score, ranging from 0% to greater than
75%. A greater reduction in extent of disease was
associated with a higher rate of CR after HDCT
(Table 6). Twenty-one patients in clinical PR had no
reduction in Swenerton score (ie, the lesions shrank,
but their numbers did not change).
Univariate analysis (Table 7) showed a reduced
likelihood of achieving a CR in patients who did not
respond to prior endocrine therapy for metastatic dis-
ease (OR 0.17; P  .01). Patients who achieved a PR
to induction chemotherapy (OR 3.33; P  .01) had a
higher likelihood of achieving a CR to HDCT than
those who had SD or PD. Patients in whom the extent
of disease at the time of transplant was greater than 6
had a lower likelihood of converting to CR (OR 0.29;
P  .01). There was a statistically signiﬁcant associa-
tion between response to induction SDCT, assessed
by percentage reduction in Swenerton score, and
conversion to CR when CR was analyzed as a con-
tinuous variable (OR 1.04; P  .01). An opportune
cut-off point of 50% reduction was identiﬁed as
signiﬁcantly associated with an increased likelihood
of conversion to CR (OR 2.48; P  .01). No differ-
ences in the likelihood of achieving a CR were seen
in patients who received less than 4 (reference
value), 4 to 7 (OR 1.0; P  .99), and greater than 7
(OR 0.90; P  .85) cycles of induction chemother-
apy (data not shown).
All the factors, regardless of whether they were
signiﬁcant at the univariate level, were included in a
saturated model and removed one at a time in a step-
wise variable-selection method until all remaining fac-
tors were statistically signiﬁcant (Table 7). A 50%
reduction in Swenerton score was associated with an
increased likelihood of conversion to CR (OR 3.32;
Figure 1. A, Overall, and B, progression-free survival rates according to response group. NoCR/CR patients showed a trend toward shorter
PFS than CR/CR patients, but this trend was not statistically signiﬁcant (P  .15).
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Table 4. Univariate Analysis of Factors Associated with PFS and OS
Variable N
PFS OS
HR P Value HR P Value
Age at transplant (yr)
<40 72 1.00 1.00
>40 160 0.81 .18 0.80 .20
Cell type
PBPC 148 1.00 1.00
BM/Mix 84 1.75 <.01 2.22 <.01
Disease stage at diagnosis*
I-II 137 1.00 1.00
IIIA/B 33 1.52 .05 1.57 .04
IV 60 0.99 .98 1.00 .99
Receptor status
ER and/or PgR 129 1.00 1.00
ER and PgR 80 1.61 <.01 1.89 <.01
Receptors unknown 23 1.35 .22 1.34 .30
Neo/adjuvant chemotherapy†
No 28 1.00 1.00
Yes 144 0.95 .81 1.37 .23
Anthracycline as adjuvant†
No 76 1.00 1.00
Yes 96 1.23 .23 1.40 .07
Adjuvant radiation therapy†
No 114 1.00 1.00
Yes 58 1.34 .11 1.40 .08
Adjuvant endocrine therapy†
No 120 1.00 1.00
Yes 50 0.83 .35 0.80 .28
Disease-free interval
>2 years 87 1.00 1.00
<2 years 145 1.29 .09 1.45 .03
Number of relapses
1 157 1.00 1.00
>1 75 1.19 .26 1.18 .32
Number of prior SDCT regimens‡
0 180 1.00 1.00
>1 40 1.18 .40 1.46 .07
Prior endocrine therapy for metastatic disease
No 189 1.00 1.00
Yes 43 1.36 .10 1.34 .13
Dominant site of disease
Soft tissue/nodes 67 1.00 1.00
Bone 71 1.18 .41 0.91 .68
Viscera, nonliver 50 1.67 .02 1.63 .03
Liver 44 2.67 <.01 2.19 <.01
Number of sites
1 110 1.00 1.00
2 76 1.55 <.01 1.70 <.01
>3 46 1.75 <.01 2.01 <.01
Visceral involvement
No 138 1.00 1.00
Yes 94 1.87 <.01 1.95 <.01
Maximum extent of disease§
<6 73 1.00 1.00
6-12 79 1.37 .09 1.58 .03
13-20 43 1.45 .10 1.90 .01
>20 37 2.62 <.01 2.80 <.01
Disease extent before HDCT§
<6 149 1.00 1.00
6-12 59 1.78 <.01 1.94 <.01
13-20 17 1.74 .05 2.12 .01
>20 7 2.91 <.01 1.76 .18
% Change in Swenerton score
>50 118 1.00 1.00
<50 114 1.43 .02 1.39 .05
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Table 5. Multivariate Analysis of Factors Associated with PFS and OS
Factor
PFS OS
HR 95% CI P Value HR 95% CI P Value
Cell type
PBPC 1.00 — — 1.00 — —
BM/Mix 1.39 1.02-1.89 .04 2.01 1.45-2.79 <.01
Hormone receptor status
ER and/or PgR 1.00 — — 1.00 — —
ER and PgR 1.89 1.36-2.63 <.01 2.13 1.48-3.07 <.01
Unknown 1.71 1.05-2.79 .03 1.42 0.80-2.55 .23
Disease-free interval
>2 years 1.00 — —
<2 years 1.62 1.13-2.34 <.01
Visceral involvement
Absent 1.00 1.00 — —
Present 1.84 1.35-2.51 <.01 1.77 1.27-2.46 <.01
Number of sites
1 1.00 — —
2 1.96 1.34-2.88 <.01
>3 2.79 1.77-4.39 <.01
% Change in Swenerton score
>50 1.00 — —
<50 2.08 1.48-2.91 <.01
Status at transplant
CR 1.00 — —
PR 2.36 1.54-3.62 <.01
SD 2.67 1.59-4.47 <.01
PD 4.21 2.24-7.92 <.01
PFS indicates progression-free survival; OS, overall survival; HR, hazards ratio; CI, conﬁdence interval; PBPC, peripheral blood progenitor
cells; BM, bone marrow; Mix, BMPBPC; ER, estrogen receptor; PgR, progesterone receptor; CR, complete response; PR, partial response;
SD, stable disease; PD, progressive disease.
*Measured by the Swenerton score.
Table 4 (continued)
Variable N
PFS OS
HR P Value HR P Value
Status before HDCT
CR 50 1.00 1.00
PR 128 2.41 <.01 2.16 <.01
SD 35 2.33 <.01 1.90 .03
PD 19 3.04 <.01 3.04 <.01
Number of cycles of induction SDCT
<4 43 1.00 1.00
4-7 145 1.03 .87 1.03 .90
>7 44 0.98 .93 0.83 .50
CVP as part of HDCT
No 86 1.00 1.00
Yes 146 1.07 .66 1.10 .59
Note. P values were calculated by the log-rank test.
PFS indicates progression-free survival; OS, overall survival; HR, hazards ratio; CI, conﬁdence interval; PBPC, peripheral blood progenitor
cells; BM, bone marrow; Mix, BMPBPC; ER, estrogen receptor; PgR, progesterone receptor; SDCT, standard-dose chemotherapy; CR,
complete response; PR, partial response; SD, stable disease; PD, progressive disease; HDCT, high-dose chemotherapy; CVP, cyclophos-
phamide, etoposide, cisplatin.
*For 2 patients, stage at diagnosis was missing.
†Excluding patients with upfront stage IV disease.
‡Number of prior chemotherapies for metastatic disease, excluding the induction treatment.
§Measured by the Swenerton score.
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P  .01). Soft-tissue disease (as opposed to visceral or
bone disease) was similarly associated with increased
likelihood of conversion to CR (OR 4.08; P  .01),
whereas patients with multiple sites of metastatic dis-
ease had decreased likelihood of conversion to CR
(OR 0.34; P  .01).
DISCUSSION
In this study of 232 patients with metastatic breast
cancer who underwent HDCT, the CR rate after
HDCT was 44%, including conversion of 53 patients
who had not achieved CR after SDCT (NoCR/CR
group). OS and PFS were not signiﬁcantly different in
CR/CR and NoCR/CR patients, although the former
had a trend toward improved PFS (44 v 22 months,
respectively; see Figure 1). Although it is possible that
with additional follow-up this difference could be-
come signiﬁcant, similar ﬁndings have been reported
by Rizzieri et al. [18]. In their experience, 58 of 199
patients receiving HDCT after a PR to chemotherapy
with doxorubicin, 5-ﬂuorouracil, and methotrexate
chemotherapy converted to CR (conversion rate 29%)
and had PFS and OS rates similar to those of patients
receiving HDCT after a CR [18]. Smaller metastatic
foci, nonvisceral disease, and lack of previous exposure
to anthracycline predicted conversion to CR.
The analysis of prognostic factors conﬁrmed the
adverse value of hormone receptor negativity, visceral
involvement, short disease-free interval from the di-
agnosis of the primary tumor to the onset of meta-
static disease, multiple sites of metastatic disease, and
failure to achieve a CR to conventional induction
chemotherapy on PFS or OS (Table 5). However,
these prognostic factors are known to affect the out-
come of any patient with metastatic breast cancer
undergoing chemotherapy, whether conventional or
high dose [5,18,21-23]. Their usefulness in selecting
the optimal candidates for HDCT is therefore lim-
ited.
Two prognostic factors we identiﬁed merit further
discussion. First, we found that the use of bone mar-
row (BM) as a source of hematopoietic reconstitution
was associated with worse PFS and OS. Although the
clinical advantages to using peripheral blood progen-
itor cells are well known, and currently bone marrow
has been almost completely abandoned in the autolo-
gous setting [24], such an effect on PFS and OS has
never been documented before in breast cancer pa-
tients undergoing HDCT [22]. This effect was also
conﬁrmed in a separate analysis excluding the 11 pa-
tients who died of acute transplant-related complica-
tions, 8 of whom were engrafted with bone marrow
cells (data not shown). One possible explanation is that
the reinfusion of large amounts of viable cancer cells
with bone marrow could have accounted for early
relapsing and progressing disease. If true, this obser-
vation would support further research in the ﬁeld of
purging the peripheral blood progenitor cell harvests
from breast cancer cells to improve on the efﬁcacy of
HDCT [25,26].
The other prognostic factor that merits discussion
is the Swenerton scoring system, use of which showed
an association between tumor response to SDCT and
OS. Patients who did not achieve at least a 50%
reduction in the Swenerton score after SDCT had
reduced survival. When studied as a predictive factor,
the assessment of tumor response by reduction in the
Swenerton score turned out to be predictive of con-
version into CR in the subset of patients who did not
achieve a CR to SDCT (Table 7). Conversion oc-
curred in 17 (20%) of 85 patients with less than 50%
reduction in the Swenerton score and in 36 (40%) of
Table 6. Conversion to Complete Remission After Induction Chemotherapy by Percent Reduction in the Swenerton Score
% Reduction in the
Swenerton Score
Overall
(n  175) CR Conversion (%)
Patients in PR
(n  127) CR Conversion (%)
0-24 59 11 (19%) 26* 6 (23)
25-49 26 6 (23%) 21 5 (24)
50-74 73 29 (40%) 66 28 (42)
>75 17 7 (41%) 14 7 (50)
CR indicates complete response; PR, partial response.
*Twenty-one patients who achieved a clinical PR did not show reductions in the Swenerton score. One patient who had achieved a PR with
radiation therapy is not included.
Table 7. Analysis of Factors Predictive of Conversion into Complete
Response
Variable
Univariate Multivariate
OR P Value OR P Value
Prior endocrine therapy for
metastatic disease 0.17 <.01
Clinical PR to SDCT 3.33 <.01
Soft tissue/nodes 3.74 <.01 4.08 <.01
> 50% Reduction in the
Swenerton score 2.48 <.01 3.32 <.01
Swenerton score >6 at time
of HDCT 0.29 <.01
Multiple sites of disease 0.61 .13 0.34 <.01
OR indicates odds ratio; PR, partial response; SDCT, standard-
dose chemotherapy; HDCT, high- dose chemotherapy.
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90 patients with  50% reduction in the Swenerton
score after SDCT. What we ﬁnd more interesting is
the conversion rate for patients achieving a PR to
induction SDCT. For those patients, the conversion
rate was on the order of 42% to 50% only for those
who achieved a 50% reduction in the Swenerton
score; those with a lesser reduction in Swenerton score
had only 23% to 24% conversion into CR (Table 5).
Notably, 21 patients in clinical PR had no reduction in
the Swenerton score (ie, the lesions shrank but did not
change in number). Having achieved either a CR or a
PR to SDCT have been a prerequisite for entering
clinical trials of HDCT for metastatic breast cancer,
which probably resulted in the inclusion of heteroge-
neous populations of patients in the published ran-
domized trials. Our results suggest that chemosensi-
tivity can be further deﬁned by extent of metastatic
disease and the tumor response to SDCT according to
the Swenerton score. The Swenerton score is thus a
potentially useful tool for designing treatment strate-
gies and clinical trials of HDCT.
HDCT with CBT and AHSCT was effective in
producing a CR in 30% of patients with metastatic
breast cancer for whom SDCT failed to produce CR.
Patients most likely to achieve CR had single rather
than multiple sites of disease, soft tissue/nodal disease,
and a  50% reduction in the Swenerton score after
conventional induction chemotherapy. Patients who
converted to CR after HDCT had remission duration
and survival similar to patients given HDCT after
achieving a CR with induction treatment. Patients
who did not achieve CR showed only brief responses.
Whether the Swenerton score can outperform the
classical “PR” criterion in assessing chemosensitivity
to SDCT and in identifying candidates to HDCT
remains to be determined. Indeed, a potential increase
in conversion rate from 20% to 40% using the Swen-
erton score could be considered only a marginal
achievement. However, a more thorough assessment
of the extent of disease and its modiﬁcations as a
consequence of SDCT identiﬁes a subset of patients
who can achieve substantial beneﬁt from HDCT.
These data warrant conﬁrmation in adequately de-
signed and powered randomized trials.
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